Recent Analysts’ Ratings Changes for Envista (NVST)

A number of firms have modified their ratings and price targets on shares of Envista (NYSE: NVST) recently:

• 8/7/2026 – Envista was upgraded by Zacks Research from “hold” to “strong-buy”.
• 8/6/2026 – Envista was upgraded by Weiss Ratings from “hold (c-)” to “hold (c)”.
• 8/6/2026 – Envista was given a new $23.00 price target by Morgan Stanley.
• 8/6/2026 – Envista was given a new $34.00 price target by Robert W. Baird.
• 8/6/2026 – Envista was given a new $29.00 price target by Mizuho.
• 8/6/2026 – Envista had its “neutral” rating reaffirmed by Piper Sandler. They now have a $28.00 price target on the stock, up from $26.00.
• 7/29/2026 – Envista had its price target raised by Piper Sandler from $25.00 to $26.00. They now have a “neutral” rating on the stock.
• 7/8/2026 – Envista is now covered by BMO Capital Markets. They set a “market perform” rating and a $27.00 price target on the stock.
• 7/8/2026 – Envista was upgraded by BMO Capital Markets to “hold”.

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.